Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Radiology and Oncology
Volume 57 (2023): Issue 2 (June 2023)
Open Access
Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report
Tobian Muir
Tobian Muir
,
Giulia Bertino
Giulia Bertino
,
Ales Groselj
Ales Groselj
,
Lakshmi Ratnam
Lakshmi Ratnam
,
Erika Kis
Erika Kis
,
Joy Odili
Joy Odili
,
Ian McCafferty
Ian McCafferty
,
Walter A Wohlgemuth
Walter A Wohlgemuth
,
Maja Cemazar
Maja Cemazar
,
Aljosa Krt
Aljosa Krt
,
Masa Bosnjak
Masa Bosnjak
,
Alessandro Zanasi
Alessandro Zanasi
,
Michela Battista
Michela Battista
,
Francesca de Terlizzi
Francesca de Terlizzi
,
Luca G Campana
Luca G Campana
and
Gregor Sersa
Gregor Sersa
| Jun 21, 2023
Radiology and Oncology
Volume 57 (2023): Issue 2 (June 2023)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Review
Published Online:
Jun 21, 2023
Page range:
141 - 149
Received:
May 26, 2023
Accepted:
Jun 03, 2023
DOI:
https://doi.org/10.2478/raon-2023-0029
Keywords
vascular malformations
,
bleomycin electrosclerotherapy
,
bleomycin
,
electrochemotherapy
© 2023 Tobian Muir et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.